Étiquette : Oncology

INOVARION

by jbertholdin Institutions, Service Providers & others

INOVARION

About the company

Inovarion is a Life Sciences company based in Paris offering preclinical and fundamental research services.

Since 2013, Inovarion provides support to the pharmaceutical, biotechnology industries and academics in the form of research services outsourced on a contract basis. They help biotech companies to reach clinical trials faster outsourcing their R&D to Inovarion in France.

They have been working as an extension of their partners’ teams for Sanofi, L’Oréal, Inserm (French NIH), Gustave Roussy, and many more.

About the solution

Inovarion has developed a strong expertise in bioinformatics, oncology, immunology and molecular biology.
They are well established in the research landscape in France and published +140 scientific papers in the highest ranked reviews (Nature, Science, The Lancet, Cell…).

Here are their main advantages:
⁃ Scientific French excellence
⁃ Cost effectiveness thanks to French tax credits : 25%-40% less vs US project cost
⁃ Talent loyalty & stability: less than 5% staff turnover per year in our team

Their goal is to build up close and long-term cooperation with pharmaceutical and biotechnologiy companies worldwide, to offer them in France, very attractive conditions, both financial and time-saving, for conducting top-notch fundamental and preclinical research and beyond that, to achieve together scientifical victories in medicine.

Website
Key information

–  Therapeutic areas: Immuno-oncology, Neuroscience, Dermatology, Oncology, Immunology

–  Based in: Paris (FRANCE)

–  Employees: 51-200

–  Created in: 2013

ARIANA PHARMACEUTICALS

by jbertholdin Digital Health

ARIANA PHARMACEUTICALS

About the company

Ariana Pharma is a leading Artificial Intelligence (AI) drug development company. Using its KEM® Artificial Intelligence (xAI) technology, Ariana helps its partners introduce personalized medicine clinical trial design into their protocols and optimize clinical endpoints, identify biomarkers of therapeutic response and potential synergistic therapies.

Ariana routinely collects and combines clinical data with omic data, immunological readouts (such as Fluorescence-Activated Cell Sorting (FACS)), microbiota, Patient Reported Outcomes (PRO) as well as Real World Evidence (RWE) data. Combining advanced data analytics, drug development, and regulatory expertise, Ariana helps translate findings into innovative clinical development plans and regulatory approvals.

With a growing number of successful therapeutic development programs, KEM® is an FDA-assessed technology that systematically explores combinations of biomarkers, producing more effective biomarker signatures for precision medicine. Founded in 2003 as a spin-off of the Institut Pasteur, Paris, France, the company operates a subsidiary in the United States since 2012.

About the solution

Ariana Pharma has developed an explainable artificial intelligence platform which explores all possible biomarker associations, generating results that can be used directly to design clinical trials and accelerate drug development. Based on the mathematical theories of Formal Concept Analysis and Gallois lattices, the power of the KEM® platform lies in its ability to deliver explainable results from small cohorts. KEM® is also effective at managing contradictions and heterogeneous data, ensuring the identification of relevant and accurate hypotheses that meet the needs of precision medicine.

Website
Key information

–  Therapeutic areas: Oncology, CNS, Cardiometabolic, Immunology

–  Based in: Paris (FRANCE)

–  Employees: 11-50

–  Created in: 2003

MABQI

by jbertholdin Biotech, Pharma

MABQI

About the company

Mabqi is a high-tech developer of human therapeutic antibodies. Its phage display core technology platform allows the development of functional antibodies (including pH-sensitive antibodies selected from our oncology-dedicated library) with high developability through proprietary synthetic human libraries. Based on the technical expertise built on more than 20 successful discovery programs (Servier, ADC Therapeutics, … ) and the clinical expertise of its Medical Advisory Board, Mabqi is actively building a portfolio of first-in-class and best-in-class proprietary antibodies with high therapeutic potential in oncology.

Some of these assets are already available for partnered development and licensing opportunities. Mabqi provides also customized discovery services, including full antibody characterization, and has developed a unique and dedicated library to select pH-dependent antibodies for oncology indications.

About the solution

Thanks to smooth integration of high throughput discovery processes and AI, Mabqi is able to propose a portfolio of outstanding, readily developable antibodies: Tumor Microenvironment Targeting through pH sensitivity, excellent affinity ranges on membrane proteins and biological functionality are combined to offer solutions even in the most complicated cases.

Website
Key information

–  Therapeutic areas: Oncology, Immune diseases

–  Based in: Montpellier (FRANCE)

–  Employees: 11-50

–  Created in: 2017

ORAKL ONCOLOGY

by jbertholdin Biotech, Digital Health, Pharma

ORAKL ONCOLOGY

About the company

The current drug development process does not capture cancer complexity or heterogeneity. This is a main reason why 96% of drugs fail when they meet patients in clinical trials, lacking efficacy in the patient population.

Orakl Oncology stands at the forefront of the techbio landscape, pioneering the use of patient tumor avatars to meticulously accelerate and de-risk drug development in collaboration with oncology players.


As a spin-out from Gustave Roussy (2023), the 4th cancer center in the world, Orakl’s boasts unique access to a vast repository of patient tissue samples and associated data. This strategic foundation positions them to scale quickly across a vast number of cancer subtypes starting with colorectal and pancreatic cancers.

The founders and team collectively bring unparalleled expertise in cancer cell biology and engineering. With over 30 years of combined academic experience across France, the UK, and the US, they are dedicated to improving cancer treatment. The company has already been funded 5M€ in equity and grants for their first developments.

About the solution

Orakl Oncology is a techbio platform that is building a unique collection of patient tumor avatars, each of them combining the best biology and patient clinical and molecular data. As a spin-out from Gustave Roussy, the 4th cancer center in the world, they are positionned to scale quickly across a vast number of cancer subtypes starting with colorectal and pancreatic cancers. This combination of biology and data, scalable and supported by proprietary know-how, is an extraordinary differenciating factor.


Their cutting-edge approach involves the integration of functional testing and AI-powered analysis to predict patient response to treatments and stratify populations. They already obtained excellent predictive values, at the patient and population levels.


Orakl discovers and develops new drugs that will succeed in the clinic, for their own pipeline or in co-development with oncology companies.

Website
Key information

–  Therapeutic areas: Oncology

–  Based in: Paris (FRANCE)

–  Employees: 1-10

–  Created in: 2023

CARTHERA

by jbertholdin Medtech

CARTHERA

About the company

Carthera is a clinical-stage company developing the SonoCloud, a revolutionary system to temporarily open the blood-brain barrier (BBB), and to improve CNS bioavailability of small molecules, ASOs, mAbs and other therapeutics. By using SonoCloud, the therapeutic efficacy of new and existing therapies can be unlocked and harnessed to improve the treatment of a wide range of brain diseases.

About the solution

SonoCloud is an intracranial implant using low-intensity pulsed ultrasound (LIPU) to temporarily open the blood-brain barrier BBB before or after the injection of therapeutics. This innovative approach is being tested in several clinical programs in Glioblastoma with different chemotherapeutic agents as well as PDL-1 & CTLA-4 antibodies. SonoCloud is now entering the neurodegeneration field with focus on ALS, Huntington Disease and Parkinson Disease.

Website
Key information

–  Therapeutic areas: Oncology, Neurodegenerative diseases

–  Based in: Lyon (FRANCE) Office in Boston (USA)

–  Employees: 11 – 50

–  Created in: 2010

PHOST’IN THERAPEUTICS

by jbertholdin Biotech, Pharma

PHOST’IN THERAPEUTICS

About the company

Phost’in develops First-in-Class N-glycosylation inhibitors for the treatment of cancers and fibrosis (First-in-Human currently on-going in Europe for the first program).

About the solution

PhOx430, First-In-Class selective GnT-V inhibitor, now evaluated in Ph.I in patients with Advance Solid Tumors.

Website
Key information

–  Therapeutic areas: Oncology, Fibrosis

–  Based in: Montpellier (FRANCE)

–  Employees: 1-10

–  Created in: 2014

CLINSEARCH

by jbertholdin Institutions, Service Providers & others

CLINSEARCH

About the company

ClinSearch is a full service European CRO, established in 1999, offering clinical research and medical evaluation services throughout Europe, as well as the Middle East and the United States.

They have conducted hundreds of studies, from phase I to IV studies, early access programs, post-marketing studies, RWE, PASS, PAES, database analyses and medico-economic studies, involving 1 patient up to 220,000 subjects.
Their customers include global and local medical device, biotechnology and pharmaceutical companies, as well as public health institutions.

About the solution

Full service offering from A to Z: methodological input to study design through to peer-reviewed publications, passing via in-house development of sophisticated healthcare tools (EDC, ePRO, …).

The in-house team of over 70 people work from our headquarters in Malakoff (France), but hail from ~15 different countries and speak over 10 languages, and are trained to a high standard (MD, PhD, PharmD, MS, MPH …).

Website
Key information

–  Therapeutic areas: Addiction, Aesthetics, Algorithm, Software, Cardiovascular, Dermatology, Fertility, Immunology, Infectiology, Hematology, Neurology, Neuromuscular, Neurovascular, Nursing care, Orthopedic, Oncology, Rheumatology, Rare diseases, Respiratory, Surgery, Urology

–  Based in: Boston (USA)

–  Employees: 51-200

–  Created in: 1999

TRUFFLE CAPITAL

by jbertholdin Biotech, Pharma

TRUFFLE CAPITAL

About the company

For 20 years, Truffle Capital has been financing innovations, growing and empowering technology leaders in healthcare & finance.

Website
Key information

–  Therapeutic areas: Infectious diseases, oncology, rheumatalogy, joint diseases, Transplants

–  Based in: Paris (FRANCE)

–  Employees: 11 – 50

–  Created in: 2001

B2G LIFE SCIENCES

by jbertholdin Institutions, Service Providers & others

B2G LIFE SCIENCES

About the company

B2G Life Sciences is a science-driven, international, medical consulting company, dedicated to clinical development.
They serve as acting CMO, yet also provide extended stand-alone as well as fully-integrated services, to the biotechnology and pharmaceutical industry, with a particular focus on rare and orphan diseases, oncology, as well as biotherapies and advanced therapies.

They have operational capacities across Europe and the Mediterranean region, as we endeavor to build bridges and gateways between operators in different markets.

About the solution

They serve as acting CMO and provide extended stand-alone as well as fully-integrated consulting services to the biotechnology and pharmaceutical industry, with a particular focus on rare and orphan diseases, oncology,
as well as biotherapeutics and advances therapies.

From study design to execution, they provide services in the following focus areas:
– Clinical development strategies and protocol development
– Management of scientific boards
– Study conduct and patient enrollment
– Medical review and medical writing
– Trainings in the busnisses of biotech and pharma industries.

Website
Key information

–  Therapeutic areas: Clinical Development Consulting services, Rare diseases, Oncology, Biotherapies, Advanced therapies

–  Based in: Sèvres (FRANCE)

–  Employees: 11 – 50

–  Created in: 2011

SATT AxLR

by jbertholdin Institutions, Service Providers & others

SATT AxLR

About the company

SATT AxLR is a TTO based in south of France with a focus on innovative health projects from academic teams. SATT AxLR is funding early stages to allow project reaching a stage for technical transfer or company creation.

About the solution

SATT AxLR provide advice, contacts, funding to academic researchers (Universities, Hospitals, Public Instittutes,..) and generate intellectual property that is available for licensing.

Website
Key information

–  Therapeutic areas: Oncology, Immunology, CNS, Cardiology, Rare diseases, Obesity, Cell therapy, Medical Device

–  Based in: Montpellier (FRANCE)

–  Employees: 11 – 50

–  Created in: 2012